A scoping review of the management of esophageal cancer and the shift toward the minimally invasive approach

Abstract

Esophageal cancer poses a significant global health burden due to its aggressive nature and challenging management. This scoping review aims to explore the evolving landscape of esophageal cancer management, focusing on the shift toward minimally invasive approaches. The review synthesizes current guidelines, staging methods, treatment modalities for early and advanced stages, and surgical options, emphasizing the growing prominence of minimally invasive techniques.

Keywords

Esophageal cancer / minimally invasive approach / esophageal squamous cell carcinoma / esophageal adenocarcinoma

References

[1] 2017 Oesophageal Cancer Collaborators. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet Gastroenterol Hepatol2020;5:582-97 PMCID:PMC7232026

[2] Lagergren J,Cunningham D.Oesophageal cancer.Lancet2017;390:2383-96

[3] Liu CQ,Qin Q.Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040.Thorac Cancer2023;14:3-11 PMCID:PMC9807450

[4] Obermannová R, Alsina M, Cervantes A, et al; ESMO Guidelines Committee. Electronic address: [e-mail]. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:992-1004.

[5] Ajani JA,Bentrem DJ.Esophageal and esophagogastric junction cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2023;21:393-422

[6] Amin MB,Greene FL. AJCC Cancer Staging Manual. Springer; 2017. Available from: https://link.springer.com/book/9783319406176. [Last accessed on 6 Nov 2024]

[7] Oo AM.Overview of gastroesophageal junction cancers.Mini-invasive Surg2019;3:13

[8] Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part I.Esophagus2017;14:1-36 PMCID:PMC5222932

[9] Kitagawa Y,Ishikawa H.Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.Esophagus2023;20:343-72 PMCID:PMC10024303

[10] van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis.Br J Cancer2008;98:547-57 PMCID:PMC2243147

[11] Thosani N,Kapadia A.Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis.Gastrointest Endosc2012;75:242-53

[12] Young PE,Acosta RD,Riddle M.Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus.Clin Gastroenterol Hepatol2010;8:1037-41

[13] Krill T,Roark R.Accuracy of endoscopic ultrasound in esophageal cancer staging.J Thorac Dis2019;11:S1602-9 PMCID:PMC6702397

[14] Gertsen EC, Brenkman HJF, van Hillegersberg R, et al; PLASTIC Study Group. 18F-fludeoxyglucose-positron emission tomography/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective dutch cohort study (PLASTIC). JAMA Surg 2021;156:e215340. PMCID:PMC8552113

[15] Stein HJ,Bruecher BL,Sarbia M.Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection.Ann Surg2005;242:566-73; discussion 573 PMCID:PMC1402356

[16] Malik S,Sanaka MR.Role of endoscopic therapy in early esophageal cancer.World J Gastroenterol2018;24:3965-73 PMCID:PMC6148428

[17] Wander P.Endoscopic management of early esophageal cancer: a literature review.Ann Esophagus2023;6:16

[18] Bollschweiler E,Schröder W.High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas.Endoscopy2006;38:149-56

[19] Fleischmann C,Messmann H.Indications for endoscopic treatment of adenocarcinoma and squamous cell cancer of the esophagus.Ann Esophagus2023;6:5-5

[20] Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002.Gastrointest Endosc2003;58:S3-43

[21] Maan ADI,Koch AD.Curative criteria for endoscopic treatment of oesophageal adenocarcinoma.Best Pract Res Clin Gastroenterol2024;68:101886

[22] Luketich JD,Awais O.Outcomes after minimally invasive esophagectomy: review of over 1000 patients.Ann Surg2012;256:95-103 PMCID:PMC4103614

[23] Stahl M,Haustermans K,Arnold D.ESMO Guidelines Working GroupOesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2013;24 Suppl 6:vi51-6

[24] van Hagen P, Hulshof MC, van Lanschot JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.

[25] Eyck BM, van Lanschot JJB, Hulshof MCCM, et al; CROSS Study Group. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol 2021;39:1995-2004.

[26] Yang H,Chen Y.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial.J Clin Oncol2018;36:2796-803 PMCID:PMC6145832

[27] Cunningham D,Stenning SP.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med2006;355:11-20

[28] Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-57.

[29] Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.Lancet2002;359:1727-33

[30] Allum WH,Bancewicz J,Langley RE.Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.J Clin Oncol2009;27:5062-7

[31] Stahl M,Riera-Knorrenschild J.Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial.Eur J Cancer2017;81:183-90

[32] von Döbeln GA,Jacobsen AB.Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.Dis Esophagus2019;32:doy078

[33] Wang H,Fang Y.Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial.JAMA Surg2021;156:444-51 PMCID:PMC7970392

[34] Kato K,Daiko H.A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.JCO2022;40:238

[35] Li B, Yang Y, Toker A, et al; Cooperative Group of International Expert Consensus on Robot-assisted Esophagectomy for Esophageal Cancer. International consensus statement on robot-assisted minimally invasive esophagectomy (RAMIE). J Thorac Dis 2020;12:7387-401. PMCID:PMC7797844

[36] Teoh AY,Yeung WK,Wong SK.Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial.Ann Oncol2013;24:165-71

[37] Al-Batran SE,Pauligk C.Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.Lancet Oncol2016;17:1697-708

[38] Homann N,Luley K.Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.Int J Cancer2012;130:1706-13

[39] Park SR,Kim JH.A randomized phase III trial on the role of esophagectomy in complete responders to preoperative chemoradiotherapy for esophageal squamous cell carcinoma (ESOPRESSO).Anticancer Res2019;39:5123-33

[40] van der Wilk B,Wijnhoven B.LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial.Ann Oncol2023;34:S1317

[41] Eyck BM, van der Wilk BJ, Noordman BJ, et al; SANO-study group. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials 2021;22:345. PMCID:PMC8127221

[42] Fang HY,Chang HK,Liu YH.Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.Dis Esophagus2017;30:1-8

[43] Boerner T,Tan KS.Waiting to operate: the risk of salvage esophagectomy.Ann Surg2023;277:781-8 PMCID:PMC10354214

[44] Kato K,Takahashi M.Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol2019;20:1506-17

[45] Kojima T, Shah MA, Muro K, et al; KEYNOTE-181 Investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 2020;38:4138-48.

[46] Huang J, Xu J, Chen Y, et al; ESCORT Study Group. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020;21:832-42.

[47] Kato K,Shah M.LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study.Ann Oncol2020;31:S1192-3

[48] Janjigian YY,Moehler M.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Lancet2021;398:27-40 PMCID:PMC8436782

[49] Kelly RJ, Ajani JA, Kuzdzal J, et al; CheckMate 577 Investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384:1191-203.

[50] Shang X,Zhao G.Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed by surgery for locally advanced oesophageal squamous cell carcinoma: protocol for a multicentre, prospective, randomized-controlled, phase III clinical study (Keystone-002).Front Oncol2022;12:831345 PMCID:PMC9008846

[51] Qin J,Hao A.Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.Nat Med2024;30:2549-57 PMCID:PMC11405280

[52] Kim TH, Kim IH, Kang SJ, et al; Development Working Groups for the Korean Practice Guidelines for Gastric Cancer 2022 Task Force Team. Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer 2023;23:3-106. PMCID:PMC9911619

[53] Yoshida K, Yasufuku I, Terashima M, et al; CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO). International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 2022;6:227-40. PMCID:PMC8889854

[54] Al-Batran SE,Pauligk C.Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial.JAMA Oncol2017;3:1237-44 PMCID:PMC5824287

[55] Matsuda S,Kato K.Defining conversion therapy for esophageal squamous cell carcinoma.Ann Gastroenterol Surg2023;7:7-9 PMCID:PMC9831898

[56] Sugimura K,Sugase T.Clinical impact of conversion surgery after induction therapy for esophageal cancer with synchronous distant metastasis: a multi-institutional retrospective study.Ann Surg Oncol2024;31:3437-47

[57] Tsuji T,Sato Y.Safety and efficacy of conversion therapy after systemic chemotherapy in advanced esophageal cancer with distant metastases: a multicenter retrospective observational study.Ann Surg Oncol2024;

[58] Terada M,Daiko H.Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).Jpn J Clin Oncol2019;49:1055-60

[59] Omloo JM,Hulscher JB.Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.Ann Surg2007;246:992-1000; discussion 1000

[60] Mimatsu K,Kawasaki A.Mediastinoscopy-assisted esophagectomy is useful technique for poor surgical-risk patients with thoracic esophageal cancer.Surg Laparosc Endosc Percutan Tech2009;19:e17-20

[61] Liu W,Zhao H.Mediastinoscopy-assisted transhiatal esophagectomy versus thoraco-laparoscopic esophagectomy for esophageal cancer: a single-center initial experience.J Thorac Dis2020;12:4908-14 PMCID:PMC7578494

[62] Fabian T,Katigbak M,Federico JA.Thoracoscopic esophageal mobilization during minimally invasive esophagectomy: a head-to-head comparison of prone versus decubitus positions.Surg Endosc2008;22:2485-91

[63] Noshiro H,Kobayashi K.Lymphadenectomy along the left recurrent laryngeal nerve by a minimally invasive esophagectomy in the prone position for thoracic esophageal cancer.Surg Endosc2010;24:2965-73

[64] Kubo N,Yamashita Y.Thoracoscopic esophagectomy in the prone position versus in the lateral position for patients with esophageal cancer: a comparison of short-term surgical results.Surg Laparosc Endosc Percutan Tech2014;24:158-63

[65] Zhang XQ,Liu LP.The prognostic value of 11^th Japanese classification and 8^th AJCC staging systems in Chinese patients with esophageal squamous cell carcinoma.J Cardiothorac Surg2023;18:251 PMCID:PMC10463410

[66] Akiyama H,Udagawa H.Radical lymph node dissection for cancer of the thoracic esophagus.Ann Surg1994;220:364-72; discussion 372 PMCID:PMC1234394

[67] Isono K,Nakayama K.Results of a nationwide study on the three-field lymph node dissection of esophageal cancer.Oncology1991;48:411-20

[68] Society for Esophageal Diseases. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: Preface, general principles, part I.Esophagus2004;1:61-88

[69] Nishihira T,Mori S.A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus.Am J Surg1998;175:47-51

[70] Kato H,Tachimori Y.Evaluation of neck lymph node dissection for thoracic esophageal carcinoma.Ann Thorac Surg1991;51:931-5

[71] Li B,Miao L.Esophagectomy with three-field versus two-field lymphadenectomy for middle and lower thoracic esophageal cancer: long-term outcomes of a randomized clinical trial.J Thorac Oncol2021;16:310-7

[72] Koen Talsma A, Shapiro J, Looman CW, et al; CROSS Study Group. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg 2014;260:786-92; discussion 792-3.

[73] Low DE,De Manzoni G.Guidelines for perioperative care in esophagectomy: enhanced recovery after surgery (ERAS^®) society recommendations.World J Surg2019;43:299-330

[74] Biere SS,Maas KW.Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.Lancet2012;379:1887-92

[75] Nuytens F, Dabakuyo-Yonli TS, Meunier B, et al; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Groups. Five-year survival outcomes of hybrid minimally invasive esophagectomy in esophageal cancer: results of the MIRO randomized clinical trial. JAMA Surg 2021;156:323-32. PMCID:PMC7890455

[76] Mariette C, Markar SR, Dabakuyo-Yonli TS, et al; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med 2019;380:152-62.

[77] Yibulayin W,Lv H.Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis.World J Surg Oncol2016;14:304 PMCID:PMC5143462

[78] Guo W,Yang S.Combined thoracoscopic-laparoscopic esophagectomy versus open esophagectomy: a meta-analysis of outcomes.Surg Endosc2016;30:3873-81

[79] van der Sluis PC,May AM.Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: a randomized controlled trial.Ann Surg2019;269:621-30

[80] Tagkalos E,Hoppe-Lotichius M.Robot-assisted minimally invasive esophagectomy (RAMIE) compared to conventional minimally invasive esophagectomy (MIE) for esophageal cancer: a propensity-matched analysis.Dis Esophagus2020;33:doz060

[81] Jin D,Yu J.Robotic-assisted minimally invasive esophagectomy versus the conventional minimally invasive one: a meta-analysis and systematic review.Int J Med Robot2019;15:e1988

[82] Yang Y,Yi J.Robot-assisted versus conventional minimally invasive esophagectomy for resectable esophageal squamous cell carcinoma: early results of a multicenter randomized controlled trial: the RAMIE trial.Ann Surg2022;275:646-53

[83] Zhang Y,Cao Y.Robotic versus conventional minimally invasive esophagectomy for esophageal cancer: a meta-analysis.Ann Surg2023;278:39-50

[84] Zhou J,Chen L,Shu Y.McKeown esophagectomy: robot-assisted versus conventional minimally invasive technique-systematic review and meta-analysis.Dis Esophagus2022;35:doac011

[85] Yang Y,Li B.Robot-assisted esophagectomy (RAE) versus conventional minimally invasive esophagectomy (MIE) for resectable esophageal squamous cell carcinoma: protocol for a multicenter prospective randomized controlled trial (RAMIE trial, robot-assisted minimally invasive Esophagectomy).BMC Cancer2019;19:608 PMCID:PMC6587242

[86] Chao YK,Wen YW.Robotic-assisted esophagectomy vs video-assisted thoracoscopic esophagectomy (REVATE): study protocol for a randomized controlled trial.Trials2019;20:346 PMCID:PMC6558787

[87] Tagkalos E,Berlth F.Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial).BMC Cancer2021;21:1060 PMCID:PMC8474742

[88] Chan KS.Exploring the learning curve in minimally invasive esophagectomy: a systematic review.Dis Esophagus2023;36:doad008

[89] van der Sluis PC, Ruurda JP, van der Horst S, Goense L, van Hillegersberg R. Learning curve for robot-assisted minimally invasive thoracoscopic esophagectomy: results from 312 cases.Ann Thorac Surg2018;106:264-71

[90] Goense L,van der Horst S.Cost analysis of robot-assisted versus open transthoracic esophagectomy for resectable esophageal cancer. Results of the ROBOT randomized clinical trial.Eur J Surg Oncol2023;49:106968